Article: BMY: Plavix Small Worry - Analyst Blog

BMY: Plavix Small Worry - Analyst Blog


Growth of mega-blockbuster Plavix is helping Bristol-Myers Squibb Company ( BMY ) drive EPS growth up near 13% in 2008. Patent expirations loom very large in Bristol's future starting in 2011 when the Plavix patent expires. That being said, the company does have an attractive mid-to-late-stage pipeline, and the company has been dramatically working to reduce costs and shed less profitable and non-core businesses.

We believe the company is an attractive take-over candidate at this level for a larger pharma name such as Sanofi-Aventis SA ( SNY ) or Pfizer Inc. ( PFE ). EPS growth at rates near the top of big pharma and a very attractive valuation ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!